Monte Rosa Therapeutics (GLUE) Net Cash Flow (2020 - 2026)

Monte Rosa Therapeutics' Net Cash Flow history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 120.57% year-over-year to $30.0 million in Q1 2026; TTM through Mar 2026 was $81.4 million, a 483.85% increase from a year earlier, with the FY2025 full-year figure at -$94.3 million, down 197.76% from the prior year.
• Net Cash Flow advanced to $30.0 million in Q1 2026 per GLUE's latest filing, from -$78.5 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $138.9 million in Q3 2025 and bottomed at -$207.8 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$3.1 million (2023), against an average of -$11.0 million.
• Across the five-year window, Net Cash Flow tumbled 816.59% in 2024 and surged 728.35% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at -$57.5 million in 2022, then jumped by 220.25% to $69.1 million in 2023, then jumped by 42.73% to $98.6 million in 2024, then plunged by 179.54% to -$78.5 million in 2025, then surged by 138.2% to $30.0 million in 2026.
• Per Business Quant, the three latest GLUE Net Cash Flow figures stand at $30.0 million (Q1 2026), -$78.5 million (Q4 2025), and $138.9 million (Q3 2025).